Advances in our ability to make cancer models from individual patients have created a great opportunity and a new need to incorporate individual patient model generation into clinical trials of experimental therapies. We can now use these models to test
therapeutics almost in real time — to identify what therapy the patient may or may not be likely to respond to and therefore, have real potential to change cancer care.
The Center for Patient Derived Models (CPDM) facilitates model availability and quality for Dana-Farber investigators and the wider cancer community. CPDM supports researchers by generation, characterization, storage, and distribution of models of various
types, including cell lines, PDX, and fresh cell preparations.
The center's goals are to:
- Develop and use novel modeling and testing methods for patient derived models.
- Increase the number of characterized patient derived models available in all adult and pediatric cancers.
- Create a centralized and specialized infrastructure and resource to enable better access to patient derived cancer modeling capabilities across Dana-Farber, Brigham and Women's Hospital, and Boston Children’s Hospital.
- Accelerate the use of patient derived cancer models as functional diagnostic assays for sensitivity testing in clinical trials and validated clinical indications.
- Develop relationships with industry to access and assess new technologies to develop, characterize, and test patient derived cancer models (and make these technologies available to Dana-Farber investigators).
Keith Ligon, MD, PhD
Kin-Hoe Chow, PhD
Principal Research Technician
Clinical Research Coordinator
To request services, view a list of services, or generate a quote, email Kin-Hoe Chow, PhD, at email@example.com or call him at 617-632-3641.